A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Ap… (NCT07371871) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
30 participantsStarted 2026-01-08
Plain-language summary
To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Gastric cancer confirmed by histopathological or cytological diagnosis;
* unresectable locally advanced or recurrent/metastatic gastric cancer;
* age 18-75 years, regardless of gender;
* ECOG score 0-2;
* previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment;
* at least one measurable lesion present according to RECIST 1.1 criteria;
* laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g/L; WBC≥4.0×10\^9/L; NEUT≥1.5×10\^9/L; PLT≥90×10\^9/L; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal;
* negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial.
Exclusion Criteria:
* Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment;
* Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction;
* Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment);
* Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded);
* Known history of allergy to any component of the study drugs;
* Subjects with active infectious diseases;
* Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interfere…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Objective Response Rate，ORR
Timeframe: Perform imaging evaluation At the end of Cycle 2 or Cycle3 (each cycle is 28 days).